Shattuck Labs initiated Phase 2a RECEPTIVE-HS1 trial of SL-325
Shattuck Labs initiated a Phase 2 clinical trial for its lead DR3 antibody candidate SL-325 in hidradenitis suppurativa. This diversifies its clinical pipeline and positions the company for future growth in the inflammatory disease therapeutics market.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed